Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoMEX:LLY -0.77%95 EV-to-OCF is 49.23 as of Aug. 01, 2026, which is 52% above its 10-year median of 32.36. GuruFocus rates MEX:LLY with a GF Score™ of 95/100 and a GF Value™ of MXN25,217.79 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 88.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Eli Lilly and Co's Enterprise Value is MXN18,434,712 Mil.
Eli Lilly and Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was MXN374,433 Mil. Therefore, Eli Lilly and Co's EV-to-OCF for today is 49.23.
The historical rank and industry rank for Eli Lilly and Co's EV-to-OCF or its related term are showing as below:
MEX:LLY'
s EV-to-OCF Range Over the Past 10 Years
Min: 14.91 Med: 32.36 Max: 229.09
Current: 51.88
During the past 13 years, the highest EV-to-OCF of Eli Lilly and Co was 229.09. The lowest was 14.91. And the median was 32.36.
MEX:LLY's EV-to-OCF is ranked worse than 88.19% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.725
vs MEX:LLY: 51.88
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eli Lilly and Co's PE Ratio (TTM) for today is calculated as:
Eli Lilly and Co's share price for today is MXN19900.00.
Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN514.715.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eli Lilly and Co EV-to-OCF Related Terms
Eli Lilly and Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's EV-to-OCF falls into.
Eli Lilly and Co's current Enterprise Value is MXN18,434,712 Mil.
Eli Lilly and Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN374,433 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (MEX:LLY) has a EV-to-OCF of 49.23 as of Aug. 01, 2026. This is 52% above median its historical median of 32.36. Over the past decade, Eli Lilly and Co's EV-to-OCF has ranged from 14.91 to 229.09. According to the industry distribution chart, Eli Lilly and Co ranks #889 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 88.2%.
Is Eli Lilly and Co's EV-to-OCF too high?
Eli Lilly and Co's current EV-to-OCF of 49.23 is 52% above median its 10-year median of 32.36. Over the past 10 years, this metric has ranged from a low of 14.91 to a high of 229.09. The Drug Manufacturers industry median EV-to-OCF is 10.73. Eli Lilly and Co's value of 49.23 is 359% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #889 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EV-to-OCF compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #889 out of 1008 companies for EV-to-OCF. This places Eli Lilly and Co in the lower half of its industry. The industry median EV-to-OCF is 10.73. Eli Lilly and Co's value of 49.23 is 359% above this benchmark. Historically, Eli Lilly and Co's own EV-to-OCF has ranged from 14.91 to 229.09 over the past decade. While the company's 10-year median is 32.36 vs. the industry median of 10.73, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.73, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current EV-to-OCF of 49.23 is 359% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EV-to-OCF is 49.23, which is 52% above median its own 10-year median of 32.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (MEX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN25,217.79, compared to a current price of MXN19,900.00 — trading 21.1% below its estimated fair value. The current EV-to-OCF is 49.23, which is 52% above median its 10-year median of 32.36 and 359% above the Drug Manufacturers industry median of 10.73. Eli Lilly and Co's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Eli Lilly and Co (MEX:LLY), the current EV-to-OCF is 49.23 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (MEX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of MXN19,900.00 is trading 21.1% below its estimated GF Value™ of MXN25,217.79.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for MEX:LLY:
EV-to-OCF: 49.23 (52% above median its 10-year median of 32.36)
GF Value™: MXN25,217.79 vs. price of MXN19,900.00 (21.1% below fair value)
Industry Position: 359% above the Drug Manufacturers median (#889 of 1008)
No single metric tells the full story. See the MEX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
95GF Score
Get the complete analysis for MEX:LLY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LLY has been successfully added to your 
